Navigation Links
Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
Date:1/7/2014

TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency (EMA). In Europe, Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrence of symptomatic venous thromboembolism (VTE). If approved, edoxaban will be authorized for marketing in all European member states.

The MAA submission is based on data from an extensive global clinical trial program that compared treatment with once-daily edoxaban to warfarin, a current standard of care for patients with atrial fibrillation (AF) or VTE. The two clinical trials that formed the basis of the submission, ENGAGE AF-TIMI 48 and Hokusai-VTE, are the largest comparative trials of a novel oral anticoagulant in these patient populations, involving 21,105 and 8,292 patients, respectively.1,2

"The submission of our MAA in Europe for edoxaban represents our long standing commitment to addressing the needs of patients living with cardiovascular diseases, including AF or VTE," said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of Research and Development, Daiichi Sankyo Co., Ltd. and President and CEO of Daiichi Sankyo, Inc. in the United States. "This milestone brings us one step closer to providing a new treatment option to patients living with AF or VTE, and we look forward to working with the EMA as it conducts its review of edoxaban."

Edoxaban is currently
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
2. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
3. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
4. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
5. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
6. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
7. Orexigen Resubmits Contrave New Drug Application
8. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
9. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
10. Omeros Submits New Drug Application to U.S. FDA for OMS302
11. Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  An effective advisory ... provide non-binding but informed guidance to pharmaceutical organizations ... on investment, it is important for leaders to ... resources. Research and consulting leader ... assist pharmaceutical and medical device executives in identifying ...
(Date:5/1/2015)... /PRNewswire/ --Research and Markets ( http://www.researchandmarkets.com/research/vzcw2v/americas_clinical ) ... Analyzer Market by Product, by End-Users - Forecast to 2019" ... Chemistry Analyzers market is estimated to grow at a CAGR ... U.S., Canada , Mexico ... (RoA) are covered in this report. The Americas ...
(Date:5/1/2015)... , May 1, 2015 Following yesterday,s release of ... D, here are five things you need to know: ... market-based structure is unique among government programs. ... D is different than other parts of Medicare and other ... that submit bids to offer prescription drug benefits to enrollees. ...
Breaking Medicine Technology:New Study Presents Insights to Advisory Board Effectiveness in the Pharmaceutical Sector 2Americas Clinical Chemistry Analyzer (Semi-Automated Clinical Chemistry and Fully-Automated Clinical Chemistry) Market - Forecast to 2019 25 Things to Know About the CMS Part D Data Release 25 Things to Know About the CMS Part D Data Release 3
(Date:5/3/2015)... Clarkston, Metamora, Michigan (PRWEB) May 03, 2015 ... ‘Like’ mark on their Facebook page. , ... patients on the many services the Practice has, it’s ... current events. , Women’s Excellence has a very strong ... +, Pinterest, Instagram and You Tube. , Women’s ...
(Date:5/3/2015)... Bubbly Walrus ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... to play on smartphones are the ones that get users ... a video game that just absorbs attention, why not exercise ...
(Date:5/3/2015)... LOUIS, Missouri (PRWEB) May 03, 2015 ... international business that will directly impact your career? ... is designed for dynamic leaders in multinational companies ... multinational company. In a changing global landscape, differences ... negotiations and relationships. The EMIB program develops the ...
(Date:5/3/2015)... Hanover, MA (PRWEB) May 03, 2015 It is ... 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been ... of Lissa organized this great family-friendly event to honor her loving ... since its inception. , Just having turned 37, Lissa suffered ... Lissa passed away on August 24, 2012. This event is designed ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
Breaking Medicine News(10 mins):Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3
... Supervised exercise was shown to be more effective than ... with peripheral artery disease. The findings from a national ... Association Scientific Sessions meeting. Rhode Island Hospital is one ... Peripheral artery disease (PAD) is a condition in ...
... TUESDAY, Nov. 15 (HealthDay News) -- Entering adulthood in a place ... 21, seems to put women, but not men, at a long-term ... "We want to make sure people know all of the consequences ... an assistant professor in the department of psychiatry at Washington University ...
... News) -- Scientists who identified a gene linked to ... targeted treatments for anxiety disorders. The researchers assessed ... called 7q11.23 duplication syndrome (Dup7q11.23) and Williams-Beuren syndrome (WBS). ... anxiety and specific phobias. It,s caused by extra copies ...
... About half of male breast cancer patients who take the ... effects such as weight gain and sexual dysfunction, which prompts ... to researchers at The University of Texas MD Anderson Cancer ... date of how the estrogen-blocking drug is tolerated in men ...
... have found a way to load more than 2 million ... The breakthrough could speed development of cancer treatments that would ... the inside. The research appears online this week in ... "The breast cancer cells that we studied were so laden ...
... A potential breakthrough in treating late-stage ovarian cancer has ... a peptide that shrinks advanced tumours and improves survival ... "We,re extremely excited about this," said Jim Petrik, a ... who conducted the research with PhD student Nicole Campbell. ...
Cached Medicine News:Health News:Exercise may be better than stents for PAD patients 2Health News:Higher Legal Drinking Age May Mean Safer Lives for Women 2Health News:Higher Legal Drinking Age May Mean Safer Lives for Women 3Health News:Gene Linked to Separation Anxiety 2Health News:Tamoxifen causes significant side effects in male breast cancer patients 2Health News:Tamoxifen causes significant side effects in male breast cancer patients 3Health News:Rice chemists cram 2 million nanorods into single cancer cell 2Health News:Discovery may help fight late-stage ovarian cancer 2
... Spirit is the premium APAP device in ... The AutoSet algorithm responds to the patients ... flow generator stores and reports comprehensive clinical ... AutoSet devices combine integrated humidification and a ...
Paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... System provides the capability to ... middle of surgery while retaining ... incision. The system is also ... for large patients while remaining ...
These retractors, made of rugged Noryl® resin, are pre-sterilized and packaged singly in double peel-pouches for easy delivery to the sterile surgical field....
Medicine Products: